FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial.

TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety endpoints during a European Phase III trial, prompting Japanese pharma giant, Takeda, to snap up its licensing rights for up to €380M. TiGenix will hope to repeat these findings in a larger study across Europe and North America. Having been awarded Orphan Designation by the FDA, the candidate’s journey to the US market should be accelerated.

Cx601 is a cell therapy for the treatment of complex perianal fistulas – a severe, debilitating complication of Crohn’s disease. Current treatment options include antibiotics, anti TNFs and surgery, but these have limited long-term efficacy and considerable safety concerns.

Boehringer Ingelheim is targeting Crohn’s disease – a market expected to be worth up to $4.2B (€3.6B) by 2022 – with its TNFɑ inhibitor, adalimumab biosimilar, Cyltezo, while TxCell is developing a T cell therapy for the condition. Also, keep an eye out for approaches using the microbiome like that of Enterome, which targets the FimH adhesin bacterial gene.

Images – BlurryMe / shutterstock.com

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.